Core Viewpoint - Hansa Biopharma is undergoing a listing hearing on the Hong Kong Stock Exchange, with ICBC International as its sole sponsor, focusing on its proprietary technologies in structural biology, translational medicine, and clinical development [1] Product Pipeline - The company has developed a product pipeline that includes one core product and nine other candidates, targeting oncology and autoimmune markets [1] - The core product, HX009, is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China [1] - HX009 is currently involved in Phase Ib/I/IIa clinical projects in China for advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [1] - A combination study of HX009 with trastuzumab for advanced triple-negative breast cancer has been approved by the National Medical Products Administration, with the first patient recruitment expected to be completed by 2026 [1] Additional Clinical Products - The company also has two major clinical-stage products: HX301, a multi-target kinase inhibitor currently in Phase II studies for glioblastoma [1] - HX044, a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein, is undergoing Phase I/IIa studies for advanced solid tumors [1]
翰思艾泰通过港交所聆讯 工银国际为独家保荐人
Zheng Quan Shi Bao Wang·2025-12-04 00:48